Evidence map›Paper›PMID 29526955›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia.

Satoshi Takakusagi, Ken Sato, Yuhei Suzuki, Yuichi Yamazaki, Takashi Kosone, Satoru Kakizaki, Motoyasu Kusano, Hitoshi Takagi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Satoshi TakakusagiDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Japan.
Ken SatoDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Yuhei SuzukiDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Japan.
Yuichi YamazakiDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Takashi KosoneDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Japan.
Satoru KakizakiDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Motoyasu KusanoDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan.
Hitoshi TakagiDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Japan.
Gunma University · JPGunma University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a unique case of hepatitis C virus (HCV)-associated renal disease without cryoglobulinemia that showed proteinuria, hypoproteinemia, ascites, and edema. Due to combination therapy with daclatasvir and asunaprevir, the patient achieved sustained virological response at week 24 of the therapy. Furthermore, the therapy caused marked amelioration of her proteinuria, ascites, edema, and hypoalbuminemia, and finally improved her estimated glomerular filtration rate. There were no adverse events, and the combination therapy was well-tolerated. We recommend that HCV eradication with antiviral therapy using direct-acting antiviral agents be attempted first for all renal disease with HCV infection, regardless of cryoglobulinemia, considering the existence of resistance-associated variants.

Indexed as

Aged, 80 and overAntiviral AgentsAscitesCarbamatesDrug Therapy, CombinationFemaleGlomerular Filtration RateHepatitis C, ChronicHumansImidazolesIsoquinolinesKidney DiseasesProteinuriaPyrrolidinesSulfonamidesValineAntiviral AgentsasunaprevirCarbamatesdaclatasvirImidazolesIsoquinolinesPyrrolidinesSulfonamidesValinecryoglobulinemiadirect-acting antiviral agentextrahepatic manifestationhepatitis C virusrenal disease

Identifiers

PMID29526955
PMCPMC6120835
OpenAlexW2794011843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.